Pfizer revenue

Pfizer's revenue was $62.58bn in fiscal 2025, down 1.6% on the year before. Since fiscal 2007 ($48.42bn) it has grown at a compound 1.6% a year. Over the last twelve months it was $63.63bn.

Revenue history

US$ billions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Pfizer: revenue history, annual
Fiscal year	2007Dec 2007	2008Dec 2008	2009Dec 2009	2010Dec 2010	2011Dec 2011	2012Dec 2012	2013Dec 2013	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMSept 2026
Revenue	48.4	48.3	49.3	65.2	61.0	54.7	51.6	52.8	52.5	40.8	40.9	41.7	81.3	101.2	59.6	63.6	62.6	63.6
Growth on the year before	—	−0.3%	+2.0%	+32.3%	−6.3%	−10.4%	−5.6%	+2.4%	−0.5%	−22.3%	+0.2%	+1.8%	+95.2%	+24.5%	−41.1%	+6.8%	−1.6%	—
Gross profit	37.2	40.2	40.8	50.4	48.5	44.8	42.0	40.5	41.3	31.8	32.9	33.2	50.5	66.8	34.6	45.8	46.5	46.7

US$ billions unless shown otherwise. Fiscal quarters.

Pfizer: revenue history, quarterly
Quarter	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026	2026 Q3Sept 2026
Revenue	17.8	13.7	14.7	16.7	17.6	14.5	15.0	16.6
Growth on the same quarter a year before	—	—	—	—	−1.2%	+5.4%	+2.6%	−0.4%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to December 31, 2025

Products and services
Line of business	Revenue	YoY
Products	$51.7B	▼ 4.0%
Royalty	$1.6B	▲ 16.0%
Pfizer Centre One	$1.3B	▲ 16.8%
Pfizer Ignite	$41M	▼ 50.0%

These categories overlap or exclude eliminations, so shares aren't shown.

Geography
Region	Revenue	Share	YoY
United States	$37.1B	59.2%	▼ 4.2%
International Developed Markets	$16.2B	25.9%	▲ 0.8%
International Emerging Markets	$9.3B	14.9%	▲ 4.9%

From Pfizer's 10-K filed February 26, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Pharmaceuticals: the closest covered companies by revenue. Last twelve months.

Company	Revenue	Growth	3-year growth a year
Pfizer	$63.63bn	1.3%	-3.2%
Merck & Co.	$66.57bn	4.6%	4.5%
Astrazeneca PLC	$58.74bn	8.6%	—
Bristol Myers Squibb	$50.03bn	4.2%	3.6%
Novo Nordisk A S	$46.82bn	11.1%	—
Lilly (Eli)	$86.46bn	45.5%	39.2%

Compare with peers

Head to head: MRK vs PFE AZN vs PFE BMY vs PFE LLY vs PFE

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Pfizer's SEC filings (10-K and 10-Q), retrieved November 3, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Pfizer.